Legend Biotech’s pipeline update lists cell therapies targeting Claudin 18.2, DLL3, GPRC5D, BCMA and other markers across autologous, allogeneic and in vivo approaches. For investors, it identifies development status and target indications, while warning that the safety and efficacy of investigational agents remain unestablished and approval is not assured.

Key Highlights

  • LB1908 and LB2102 have met their primary endpoints and are in patient follow-up.
  • Allogeneic candidates include programs for relapsed or refractory autoimmune diseases and B-cell non-Hodgkin lymphoma.
  • LB2505 is initiating development for relapsed or refractory multiple myeloma under the company’s Johnson & Johnson collaboration terms.

Legend Biotech Corp (NASDAQ: LEGN) outlined a cell therapy pipeline spanning targets including Claudin 18.2, DLL3, GPRC5D and BCMA. The portfolio covers autologous, allogeneic and in vivo approaches, with CARVYKTI programs in patient follow-up or enrolling across newly diagnosed multiple myeloma settings.

LB2102, targeting DLL3 in second-line or later small cell lung cancer and large neuroendocrine carcinoma, has also met its primary endpoint and is in follow-up. LB2401, LB2402 and LB2403 are in patient follow-up for relapsed or refractory multiple myeloma, while LB2502 is enrolling patients for the same disease. Allogeneic programs include LB2404D and LB2405 for relapsed or refractory autoimmune diseases, plus LB2302, LB2303 and LB2406 for relapsed or refractory B-cell non-Hodgkin lymphoma. The in vivo group lists enrolling programs LB2501 for B-cell non-Hodgkin lymphoma and LB2503 for multiple myeloma, while LB2505 is initiating in multiple myeloma. The pipeline also identifies development labels including NDA, Phase III, Phase II, Phase I, preclinical and multi-regional clinical trial. The update states that some programs are confidential and may not appear in the list.